Eli Lilly and Company

NYSE:LLY Lagerbericht

Marktkapitalisierung: US$949.7b

Eli Lilly Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 4/6

Eli Lilly verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 31.1%, während die Gewinne der Branche Pharmaceuticals jährlich um gewachsen und zwar um 9.7%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 20.8%. Die Eigenkapitalrendite von Eli Lilly beträgt 81% und die Nettomargen betragen 35%.

Wichtige Informationen

31.07%

Wachstumsrate der Gewinne

31.32%

EPS-Wachstumsrate

Pharmaceuticals Wachstum der Industrie5.95%
Wachstumsrate der Einnahmen20.77%
Eigenkapitalrendite81.02%
Netto-Marge34.99%
Nächste Ertragsaktualisierung05 Aug 2026

Jüngste Aktualisierungen vergangener Leistungen

Analyseartikel • Nov 07

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...

Recent updates

Seeking Alpha • May 19

Eli Lilly Is A Buy (Technical Analysis)

Summary Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. Despite an 'F' valuation grade, LLY's growth, profitability, and upward earnings revisions reinforce its investment appeal. Recent earnings beat expectations, with Q1 EPS of $8.55 and revenue of $19.8B; 2026 guidance was raised. Institutional accumulation is evident, and I would reconsider my position only if LLY closes below its 30-week EMA. Read the full article on Seeking Alpha
Narrativ-Update • May 07

LLY: Obesity Pricing Pressure And Safety Headlines Will Shape Future Franchise Economics

Analysts have raised Eli Lilly's implied fair value from $883.99 to $899.73 after several firms increased their price targets by $1 to $50, citing confidence in the obesity and diabetes pipeline, Foundayo's regulatory progress, and clarifications around recent safety concerns. Analyst Commentary Recent research on Eli Lilly reflects a mix of enthusiasm around obesity and diabetes assets and a clearer, more cautious minority that is focused on how much optimism is already reflected in the stock.
Narrativ-Update • Apr 20

LLY: Obesity And Diabetes Platform Will Support Premium Positioning Beyond 2030

Analysts have slightly raised their average price targets on Eli Lilly in recent weeks, citing supportive trial updates in obesity and diabetes, favorable comparisons to competing GLP-1 therapies, and regulatory progress that they say supports high but unchanged fair value estimates of around $1,500. Analyst Commentary Recent Street research around Eli Lilly has been active, with a cluster of price target moves, rating changes, and product specific notes that give you a clearer sense of how professionals are framing the risk and reward.
Narrativ-Update • Apr 06

LLY: Oral GLP-1 Launch And Capacity Expansion Will Drive Future Obesity Upside

Analysts have nudged Eli Lilly's price target slightly higher by $1, reflecting updated views on obesity and diabetes franchises following recent Foundayo approval commentary and comparative GLP-1 data. Analyst Commentary Recent research on Eli Lilly clusters around obesity and diabetes, pricing dynamics in GLP-1 therapies, and the implications of new product approvals and trial readouts for long term growth and valuation.
Neues Narrativ • Mar 25

Eli Lilly: A Pipeline-Driven Growth Story Trading 30% Below What the Business Is Actually Worth

Eli Lilly already runs one of the fastest-growing drug businesses on earth, and its most powerful drug is not even approved yet. WHERE THE STOCK SITS TODAY The current price is around $907 (25/03/2026).
Narrativ-Update • Mar 23

LLY: Obesity And Diabetes Franchise Strength Will Support Premium Positioning

Analysts have raised their price target for Eli Lilly to $1,500, citing updated models that reflect slightly stronger assumed revenue growth, a marginally higher profit margin profile, and continued confidence in the obesity and diabetes franchises following recent trial data and supportive sell side research. Analyst Commentary Recent research highlights a split view on Eli Lilly, with some bullish analysts leaning into the obesity and diabetes opportunity set, while at least one more cautious voice questions how much growth is already reflected in the share price.
Narrativ-Update • Mar 09

LLY: Obesity Drug Leadership And Pipeline Catalysts Will Sustain Premium Positioning

The updated analyst price target for Eli Lilly has increased to $1,490.52 from $1,429.89. Analysts highlight the obesity and GLP-1 franchise, premium valuations tied to weight loss leadership, and potential upside from pipeline and acquisition catalysts as key factors supporting this change.
Narrativ-Update • Feb 23

LLY: GLP-1 Obesity Leadership Will Drive Future Cardiometabolic And M&A Upside

Eli Lilly's analyst price targets have shifted higher, with our fair value estimate moving from $1,093.22 to $1,211.21, as analysts point to sustained GLP-1 obesity leadership, premium valuation support, and an expanding cardiometabolic pipeline as key drivers of their updated views. Analyst Commentary Recent Street research on Eli Lilly clusters around a few clear themes, with bullish analysts focusing on obesity leadership, cardiometabolic breadth, and M&A, while more cautious voices watch valuation and execution risk around the pipeline.
Narrativ-Update • Feb 08

LLY: Government Pricing Deals Will Compress Obesity Franchise Economics Going Forward

Analysts have raised their fair value estimate for Eli Lilly from US$770 to about US$884 per share, reflecting updated assumptions on long term obesity opportunities, recent price target increases across several firms, and steady expectations around margins and future P/E multiples. Analyst Commentary The latest batch of research on Eli Lilly revolves around its weight loss and cardiometabolic franchises, expectations for new product launches, and the implications of recent policy developments on pricing and access.
Analyseartikel • Feb 07

Eli Lilly and Company (NYSE:LLY) Just Released Its Yearly Earnings: Here's What Analysts Think

Investors in Eli Lilly and Company ( NYSE:LLY ) had a good week, as its shares rose 2.0% to close at US$1,058 following...
Narrativ-Update • Jan 25

LLY: Government GLP 1 Pricing Deals Will Pressure Obesity Margins

Analysts have nudged their price targets on Eli Lilly slightly higher, citing continued confidence in the obesity and GLP 1 franchise, supportive government pricing agreements, and potential upside from acquisitions and pipeline catalysts, even as some firms fine tune their models and individual targets by low single digit amounts such as Guggenheim's recent US$2 trim. Analyst Commentary Recent research on Eli Lilly has been dominated by optimism around obesity treatments and government pricing agreements, but there is also a pocket of caution that is worth paying attention to if you are thinking about valuation, execution and long term growth risk.
Narrativ-Update • Jan 11

LLY: GLP-1 Pricing Deals Will Pressure Obesity Margins Going Forward

Analysts lifted their fair value estimate for Eli Lilly from US$650 to US$770, citing higher assumed profit margins, a slightly higher discount rate, updated expectations for revenue growth and future P/E, and continued Street support related to the obesity franchise, GLP-1 pricing agreements, and pipeline catalysts. Analyst Commentary Recent Street research around Eli Lilly has been dominated by views on obesity drugs, pricing agreements with the U.S. government, and the company’s expanding pipeline.
Narrativ-Update • Dec 27

LLY: GLP-1 Pricing Deals And Policy Will Shape Future Obesity Leadership And Risks

Analysts have lifted their fair value estimate for Eli Lilly to approximately $1,093 from about $1,024, reflecting expectations for stronger long term GLP 1 driven revenue growth, expanding profit margins and sustained leadership in the obesity market, supported by recent U.S. reimbursement and pricing deals. Analyst Commentary Street research remains broadly constructive on Eli Lilly, with a series of upward price target revisions and fresh coverage initiations underscoring confidence in the durability of its GLP 1 franchise and broader innovation pipeline.
Narrativ-Update • Dec 13

LLY: Government Access Deals Will Drive Durable Obesity And Diabetes Leadership

Analysts have raised their fair value estimate for Eli Lilly shares from approximately $1,170 to about $1,430 per share, reflecting higher expected profitability and sustained leadership in the GLP 1 obesity and diabetes market, supported by recent U.S. government access deals and upcoming launches such as orforglipron. Analyst Commentary Bullish analysts continue to frame Eli Lilly as a core beneficiary of the expanding obesity and diabetes treatment market, with valuation upside tied to both higher GLP 1 penetration and a broadening metabolic pipeline.
Narrativ-Update • Nov 29

LLY: Upcoming Price Discounts And Policy Decisions Will Influence Drug Market Leadership And Risks

Eli Lilly's analyst price target has increased by approximately $21 to $1,024. Analysts cite earnings upside, expanding obesity drug opportunities, and recently announced government reimbursement agreements as key drivers of improved growth and profitability expectations.
Analyseartikel • Nov 25

Investors Appear Satisfied With Eli Lilly and Company's (NYSE:LLY) Prospects As Shares Rocket 30%

Despite an already strong run, Eli Lilly and Company ( NYSE:LLY ) shares have been powering on, with a gain of 30% in...
Narrativ-Update • Nov 21

GLP-1 drugs part of medicare

Short update, this is more bullish news about the demand for GLP-1 drugs in general spurring growth in this type of weight loss drug. Also, earnings report have showed that increase in earnings have been driven by increase in volume of GLP-1 drugs.
Narrativ-Update • Nov 15

LLY: Upcoming Drug Price Reductions and Policy Debates Will Shape Future Opportunities and Risks

The analyst price target for Eli Lilly has increased by over $80 to approximately $1,003 per share. Analysts point to accelerating revenue growth, higher profit margins, and ongoing strength in the company's obesity drug franchise as drivers of greater long-term value.
Analyseartikel • Nov 07

Eli Lilly (NYSE:LLY) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Eli Lilly and Company's ( NYSE:LLY ) stock was strong after they recently reported robust earnings. However, we think...
Narrativ-Update • Nov 01

LLY: Upcoming Drug Launches And Global Expansion Will Shape Future Outlook

Eli Lilly’s fair value estimate has increased from $891.62 to $919.33. This reflects analysts' upward price target revisions following stronger than expected quarterly results and an improved earnings outlook.
Neues Narrativ • Sep 19

Eli Lilly's Future Growth Driven by Tirzepatide and Favorable Market Conditions

Catalysts Mounjaro/Zepbound: Lilly’s tirzepatide franchise is the engine of growth. Mounjaro (for type 2 diabetes) and Zepbound (obesity) each grew rapidly in 2024.

Aufschlüsselung der Einnahmen und Ausgaben

Wie Eli Lilly Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NYSE:LLY Einnahmen, Ausgaben und Erträge (USD Millions)
DatumEinnahmenGewinnAllgemeine und VerwaltungskostenF&E-Ausgaben
31 Mar 2672,24925,27711,56014,113
31 Dec 2565,17920,64011,09413,337
30 Sep 2559,42118,41210,51312,559
30 Jun 2553,25913,8009,87111,827
31 Mar 2549,00411,1069,22611,202
31 Dec 2445,04310,5908,59410,991
30 Sep 2440,8638,3707,63310,531
30 Jun 2438,9237,3427,33710,206
31 Mar 2435,9326,1387,1449,851
31 Dec 2334,1245,2407,4049,313
30 Sep 2332,0734,9886,6828,747
30 Jun 2329,5166,4986,5158,140
31 Mar 2327,6915,6876,2367,566
31 Dec 2228,5416,2456,0687,191
30 Sep 2229,2406,0336,0377,093
30 Jun 2229,0715,6926,0206,996
31 Mar 2229,3236,1296,1046,869
31 Dec 2128,3185,5826,1426,931
30 Sep 2127,7595,9726,1196,870
30 Jun 2126,7266,0716,0696,631
31 Mar 2125,4866,0935,8676,366
31 Dec 2024,5406,1945,8695,976
30 Sep 2023,2145,5736,0195,829
30 Jun 2022,9505,6185,9245,745
31 Mar 2023,0875,5336,0485,757
31 Dec 1922,3204,6386,0045,595
30 Sep 1921,8434,2645,9845,405
30 Jun 1921,6734,1036,0195,305
31 Mar 1921,6222,5455,9135,174
31 Dec 1821,4933,1515,7355,051
30 Sep 1822,0163725,8555,146
30 Jun 1822,368-1665,9755,205
31 Mar 1822,6071,0746,2105,207
31 Dec 1719,974-865,7335,096
30 Sep 1722,4712,2256,4755,321
30 Jun 1722,0052,4476,5265,217
31 Mar 1721,5852,1876,4835,281
31 Dec 1621,2222,7386,3305,310
30 Sep 1620,8372,4446,4605,238
30 Jun 1620,6052,4666,4715,145
31 Mar 1620,1792,3196,4834,978
31 Dec 1519,9592,4086,5334,796
30 Sep 1519,7042,3596,5354,538
30 Jun 1519,6202,0596,6314,638

Qualität der Erträge: LLY einen hohen Anteil an unbarem Gewinn hat.

Wachsende Gewinnspanne: LLYDie aktuellen Gewinnspannen (35%) sind höher als im letzten Jahr (22.7%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: LLYIn den letzten 5 Jahren sind die Einnahmen von 31.1% pro Jahr erheblich gestiegen.

Beschleunigtes Wachstum: LLYDas Gewinnwachstum des Unternehmens im letzten Jahr (127.6%) übertrifft seinen 5-Jahres-Durchschnitt (31.1% pro Jahr).

Erträge im Vergleich zur Industrie: LLY Das Gewinnwachstum im vergangenen Jahr (127.6%) übertraf das der Branche Pharmaceuticals -5% .

Eigenkapitalrendite

Hohe Eigenkapitalrendite: Die Eigenkapitalrendite von LLY(81.02%) ist zwar hervorragend, doch ist diese Kennzahl aufgrund der hohen Verschuldung des Unternehmens verzerrt.

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/26 05:38
Aktienkurs zum Tagesende2026/05/22 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Eli Lilly and Company wird von 53 Analysten beobachtet. 28 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg